BUZZ-Scholar Rock gains as muscle disorder drug gets priority US review

** Scholar Rock's shares SRRK.O up 3.4% premarket

** Co says U.S. FDA accepts SRRK's drug, apitegromab, for priority review with a decision expected by Sept 22; EU's medicines regulator has also accepted drug for review

** Co's drug treats spinal muscular atrophy, which stops production of a protein necessary for neuromuscular development and leaves children too weak to walk, talk and swallow

** In a late-stage study, patients given apitegromab saw better improvement in motor function than those given a placebo

** As of last close, SRRK up nearly 17% so far this year

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))